MARKET

ONCS

ONCS

Oncosec Med Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7868
-0.0732
-8.51%
Closed 16:00 06/24 EDT
OPEN
0.8500
PREV CLOSE
0.8600
HIGH
0.9030
LOW
0.7868
VOLUME
60.62K
TURNOVER
39.05K
52 WEEK HIGH
4.250
52 WEEK LOW
0.6700
MARKET CAP
30.97M
P/E (TTM)
-0.8169
1D
5D
1M
3M
1Y
5Y
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, announced that ...
PR Newswire · 2d ago
BRIEF-Oncosec Medical Inc Received Notice From Nasdaq That Co Is Not In Compliance With Minimum Bid Price Listing To List On Nasdaq
reuters.com · 06/03 20:36
OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Award presented by the Triple Negative Breast Cancer (TNBC) Foundation. OncoSec's Head of Patient Advocacy, Kimberly Irvi...
PR Newswire · 05/23 12:00
Robert Arch joins OncoSec Medical as CEO
OncoSec Medical (NASDAQ:ONCS) has appointed Robert Arch as President and CEO. Arch has over 28 years of experience, extending from academia to the pharmaceutical industry. He was previously Head of
Seekingalpha · 04/29 12:07
BRIEF-OncoSec Appoints Robert Arch as President and CEO
reuters.com · 04/29 12:07
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 03/28 13:07
--BTIG Adjusts OncoSec Medical's Price Target to $5 From $10, Reiterates Buy Rating
MT Newswires · 03/16 10:10
OncoSec appoints new finance chief
OncoSec Medical Incorporated (NASDAQ:ONCS) has appointed George Chi as Chief Financial Officer. Mr. Chi joins from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the
Seekingalpha · 02/23 10:41
More
No Data
Learn about the latest financial forecast of ONCS. Analyze the recent business situations of Oncosec Med Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ONCS stock price target is 7.50 with a high estimate of 10.00 and a low estimate of 5.00.
High10.00
Average7.50
Low5.00
Current 0.7868
EPS
Actual
Estimate
-0.30-0.22-0.15-0.07
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 5.43M
% Owned: 13.79%
Shares Outstanding: 39.37M
TypeInstitutionsShares
Increased
7
373.79K
New
1
8.19K
Decreased
11
284.10K
Sold Out
6
342.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Director
Linda Shi
President/Chief Executive Officer
Robert Arch
Chief Financial Officer
George Chi
Chief Accounting Officer/Vice President - Finance/Controller
Robert Delaversano
Director
Kevin Smith
Director
Chao Zhou
Independent Director
James Demesa
Independent Director
Joon Kim
Independent Director
Herbert Lyerly
No Data
No Data
About ONCS
OncoSec Medical Incorporated is a late-stage biotechnology company. The Company is focused on designing, developing and commercializing therapies and medical approaches for the treatment of cancer. Its core technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral electroporation (EP) delivery devices, such as the OncoSec Medical System (OMS) Electroporation device (OMS EP) device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its lead product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO), with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.

Webull offers kinds of OncoSec Medical Inc stock information, including NASDAQ:ONCS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCS stock methods without spending real money on the virtual paper trading platform.